Cargando…

Validation of early myocardial gadolinium enhancement (EGE) evaluation with "Lake Louise consensus" criteria in patients with suspected myocarditis using a single bolus of 0.1 mmol/Kg of a high relaxivity gadolinium-based contrast agent

Detalles Bibliográficos
Autores principales:	Galea, Nicola, Carbone, Iacopo, Fiorelli, Andrea, Noce, Vincenzo, Ciolina, Federica, Francone, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328153/ http://dx.doi.org/10.1186/1532-429X-17-S1-P292

Ejemplares similares

TI nulling and contrast conditions with a 0.15 mmol/kg dosage of MultiHance as compared to the standard 0.2 mmol/kg gadolinium dosage in patients with myocardial infarcts
por: Yamrozik, June A, et al.
Publicado: (2009)

Use of the new Lake Louise Criteria improves CMR detection of atypical forms of acute myocarditis
por: Cundari, Giulia, et al.
Publicado: (2020)

Late gadolinium enhancement characteristics in giant cell myocarditis
por: Yang, Shujuan, et al.
Publicado: (2021)

Evaluation of Early Gadolinium Enhancement (EGE) and Cardiac Functional Parameters in Cine-Magnetic Resonance Imaging (MRI) on Artificial Intelligence in Patients with Acute Myocarditis: A Case-Controlled Observational Study
por: Yuan, Wei-Feng, et al.
Publicado: (2019)

Effect of Neodymium Doping on MRI Relaxivity of Gadolinium Oxide Nanoparticles
por: B., Divband, et al.
Publicado: (2020)

Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T
por: Clauser, Paola, et al.
Publicado: (2018)

Right ventricle late gadolinium enhancement in cardiac sarcoidosis: a case series
por: Lydell, Carmen P, et al.
Publicado: (2011)

Split dose versus single bolus gadolinium administration in ecv calculation at 3 tesla cmr
por: McDiarmid, Adam K, et al.
Publicado: (2015)

Quantitative Assessment of Late Gadolinium Enhancement and Edema at Cardiac Magnetic Resonance in Low-Risk Myocarditis Patients
por: Monti, Caterina Beatrice, et al.
Publicado: (2022)

Association between ECG parameters and late gadolinium enhancement along the course of myocarditis
por: Károlyi, Mihály, et al.
Publicado: (2023)

Quantitative assessment of diffuse myocardial fibrosis in II-type diabetes mellitus patients using T1 mapping technique: preliminary data
por: Galea, Nicola, et al.
Publicado: (2016)

Segmental late gadolinium enhancement and gadolinium extracellular volume in hypertrophic cardiomyopathy
por: Levine, Jonathan M, et al.
Publicado: (2016)

Single bolus versus split dose gadolinium administration in extra-cellular volume calculation at 3 Tesla
por: McDiarmid, Adam K, et al.
Publicado: (2015)

Association of QRS-T angle and Late Gadolinium Enhancement in patients with a Clinical Suspicion of Myocarditis
por: Jensen, C.J., et al.
Publicado: (2021)

Comparison of gadolinium dose and acquisition time for late gadolinium enhancement at 3.0 T
por: Doltra, Adelina, et al.
Publicado: (2014)

Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy
por: Chan, Raymond H, et al.
Publicado: (2015)

Early gadolinium enhancement for the detection of myocardial oedema (EGE vs T2-STIR vs ACUT2E): a new method to assess the area at risk?
por: McAlindon, Elisa, et al.
Publicado: (2012)

Improving Longitudinal Transversal Relaxation Of Gadolinium Chelate Using Silica Coating Magnetite Nanoparticles
por: Xu, Kai, et al.
Publicado: (2019)

Cerium Oxide Nanoparticles with Entrapped Gadolinium for High T(1) Relaxivity and ROS-Scavenging Purposes
por: Eriksson, Peter, et al.
Publicado: (2022)

Large Protein Assemblies for High-Relaxivity Contrast Agents: The Case of Gadolinium-Labeled Asparaginase
por: Licciardi, Giulia, et al.
Publicado: (2022)

Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats
por: Robert, Philippe, et al.
Publicado: (2016)

Prognostic significance of regional edema and quantitative assessment of late gadolinium enhancement in patients with acute myocarditis
por: Vermes, Emmanuelle, et al.
Publicado: (2011)

Motion-corrected free-breathing late gadolinium enhancement combined with a gadolinium contrast agent with a high relaxation rate: an optimized cardiovascular magnetic resonance examination protocol
por: Yan, Cui, et al.
Publicado: (2020)

Inter-center variability in the application of the Lake Louise Criteria to the diagnosis of myocarditis
por: Mikami, Yoko, et al.
Publicado: (2016)

Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus
por: Schelbert, Erik B, et al.
Publicado: (2011)

Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity
por: Robic, Caroline, et al.
Publicado: (2019)

Design of High-Relaxivity Polyelectrolyte Nanocapsules Based on Citrate Complexes of Gadolinium(III) of Unusual Composition
por: Burilova, Evgenia, et al.
Publicado: (2021)

The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review
por: Olchowy, Cyprian, et al.
Publicado: (2017)

Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain
por: Taoka, Toshiaki, et al.
Publicado: (2018)

Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents
por: Richter, Henning, et al.
Publicado: (2020)

Gadolinium-Based Paramagnetic Relaxation Enhancement Agent Enhances Sensitivity for NUS Multidimensional NMR-Based Metabolomics
por: Honrao, Chandrashekhar, et al.
Publicado: (2021)

Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent
por: Lohrke, Jessica, et al.
Publicado: (2022)

The EGEE infrastructure
por: Bird, Ian
Publicado: (2006)

On the coherent scattering length of natural gadolinium
por: Frank, A I, et al.
Publicado: (2002)

Gadolinium contrast agents: Over exposure?
por: Biederman, Robert W, et al.
Publicado: (2016)

Gadolinium Deposition in the Brain: Current Updates
por: Choi, Jin Woo, et al.
Publicado: (2019)

Hypersensitivity to Gadolinium-Based Contrast Media
por: Gracia Bara, M. Teresa, et al.
Publicado: (2022)

Fatal Allergic Reaction to Gadolinium Contrast
por: Chalise, Som N, et al.
Publicado: (2023)

Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents
por: Ferreira, Vanessa M, et al.
Publicado: (2014)

Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate
por: Gallegos, Cesia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5qfdp7pa2c98c670sbcii93svh